Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.
Saved in:
| Title: | Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer. |
|---|---|
| Authors: | Gallagher L; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Xiao J; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Hsueh J; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Shah S; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Danner M; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Zwart A; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Ayoob M; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Yung T; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Simpson T; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Fallick M; Medical Science Department, Myovant Sciences, Inc, United States., Kumar D; Biotechnology Research Institute, North Carolina Central University, Durham, NC, United States., Leger P; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Dawson NA; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Suy S; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Collins SP; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2023 Oct 17; Vol. 13, pp. 1289249. Date of Electronic Publication: 2023 Oct 17 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
